Meeting
2023 ASCO Annual Meeting
Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.
Authors
Justin M. Watts
University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL
Justin M. Watts , Prapti Arvind Patel , Sung Choe , Xiaofei Bai , Dylan M. Marchione , Eytan M. Stein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02074839
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7036)
DOI
10.1200/JCO.2023.41.16_suppl.7036
Abstract #
7036
Poster Bd #
166
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Mutational landscape and clinical characterization of over 17,000 patients with myeloid malignancies using real-world data.
First Author: Taylor J. Jensen
Poster
2022 ASCO Annual Meeting
Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.
First Author: Stéphane De Botton
Poster
2021 ASCO Annual Meeting
TP53/NPM1-mutated acute myeloid leukemia as a molecularly distinct disease entity.
First Author: Frank J Scarpa
First Author: Kenneth Joel Bloom